Hamoadsorpion in Patients With Septic Shock: Efficacy and Safety Evaluation (HAdSS)
Hamoadsorpion in Patients With Septic Shock: Efficacy and Safety Evaluation. A Pilot Multicenter Randomized Controlled Trial
The study will include patients aged 18 to 80 years with a verified diagnosis of septic shock according to SEPSIS 3 criteria, diagnosed within 12 hours, and a SOFA score of 9 or more.
The minimum waiting time after diagnosis of septic shock and initiation of basic therapy before inclusion of the patient in the study therapy is 4 hours.
In addition to Standard of Care (SOC), blood purification, including hemoadsorption, will be used.
The choice of procedure will be based on the EAA (Endotoxin Activity Assay) result:
- for an EAA level of 0.6-0.9, selective lipopolysaccharide (LPS) adsorption with duration from 2 to 10 hours;
- for an EAA level less than 0.6, inflammatory mediator adsorption with duration from 6 to 12 hours.
The choice of a specific adsorbers within the LPS and inflammatory mediator sorption group will be based on randomization.
The use of LPS adsorption is planned based on randomization: Toramyxin R-20 or Efferon LPS. The use of inflammatory mediator adsorption is planned based on randomization: Jafron (HA 330) or CytoSorb.
Every patient will receive 2 adsorption procedures. The second procedure will be initiated no later than 24 hours after the initiation of the first procedure.
LPS adsorption will be performed in 38 patients (Efferon LPS in 19 patients and Toramyxin in 19 patients), two procedures per patient.
Inflammatory mediator adsorption will be performed in 38 patients (Jafron HA 330 in 19 patients and CytoSorb in 19 patients), two procedures per patient.
Sample size calculations were performed separately for each treatment cohort. For the endotoxemia cohort (EAA level of 0.6-0.9), this randomized trial is designed to compare Efferron LPS and Toraymyxin with respect to change in SOFA score at 72 hours.
At present, no universally accepted minimal clinically important difference (MCID) has been established for the SOFA score in patients with septic shock. Therefore, the assumed treatment effect was derived from published evidence and expert clinical judgment.
In the EUPHAS trial, polymyxin B hemoperfusion was associated with a mean reduction in SOFA score of approximately 3.4 points at 72 hours, whereas minimal change was observed in the control group. Similarly, the LASSO study demonstrated substantial improvement in organ dysfunction following endotoxin adsorption therapy.
For the inflammatory mediator adsorption cohort (EAA level less than 0.6), this randomized trial is designed to compare CytoSorb and Jafron HA 330 with respect to change in SOFA score at 72 hours.
In the retrospective study Mehta et al., CytoSorb hemoperfusion was associated with a mean reduction in SOFA score of approximately 2.0 points after treatment in survival group. Similarly, the case series Onuk et al. demonstrated substantial improvement in organ dysfunction following inflammatory adsorption therapy with Jafron HA 330 with a mean reduction in SOFA score of approximately 3.5 points at 72 hours.
A between-group difference of 2.5 SOFA points was considered clinically meaningful for both Endotoxin hemoadsorption and inflammatory mediators hemoadsorption because it represents a substantial proportion of the treatment effect observed in previous hemoperfusion studies and corresponds to a clinically relevant difference in the degree of organ dysfunction improvement.
The sample size for both groups (LPS and inflammatory mediator adsorption) was calculated based on the following assumption: the primary endpoint was the change in SOFA score at 72 hours (ΔSOFA); the expected between-group difference - 2.5 points on the SOFA score; standard deviation of ΔSOFA - 2.5 points; equal allocation ratio (1:1); two-sided significance level (α) of 0.05; statistical power of 80%.
Sample size estimation was performed in R using the power.t.test() function. The calculation yielded a required sample size of 16.7 patients per group. Therefore, a minimum of 17 patients per group (34 patients in total) is required to achieve the planned statistical power.
To account for an anticipated 10% dropout rate, the final sample size will be 19 patients per group (38 patients in total for LPS+ 38 patients in total for Inflammatory mediators adsorption. 76 patients in total).
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Study Inclusion Algorithm
- Diagnosis of septic shock.
- SOFA score calculation.
- Definition of inclusion/exclusion criteria.
- Obtaining informed consent.
- Determining EAA. Selecting the procedure modality (LPS adsorption/inflammatory mediator adsorption).
- Database registration. Obtaining randomization data.
- Selecting a specific device based on randomization.
- Initial data collection.
- Initiating the first procedure.
When a patient is enrolled in the study and is ready to begin the hemoadsorption procedure, the following parameters are assessed:
- Dose of norepinephrine (mcg/kg/min).
- Dose of alternative vasopressors: epinephrine (mcg/kg/min), dopamine (mcg/kg/min), phenylephrine (mcg/kg/min), dobutamine (mcg/kg/min), terlipressin (mcg/kg/min). VIS will be calculated.
- Mean arterial pressure (MAP) based on invasive hemodynamic monitoring.
- Fractional oxygen content (%).
- Diuresis rate over 12 hours (ml/kg/hour).
Blood sampling:
Arterial blood acid-base balance:
- Arterial blood lactate level (mmol/L).
- PaO2- Partial pressure of oxygen in arterial blood (mmHg).
Blood chemistry panel:
- Total bilirubin level (μmol/L).
- Direct bilirubin level (μmol/L).
- Indirect bilirubin level (μmol/L).
- Procalcitonin level (ng/ml).
- C-reactive protein (CRP) level (mg/L).
- Creatinine level (μmol/L).
- Ferritin level (μg/L).
Complete blood count White blood cell count
- Absolute neutrophil count (cells/µL).
- Absolute lymphocyte count (cells/µL).
- Absolute platelet count (10.9 /L).
- Blood collection for immunological testing (IL 6, IL 10, TNF).
Upon patient enrollment in the study, a description of the CRRT procedure parameters, dialysis membrane type, anticoagulation type, antibacterial agents, and suspected infectious agents is provided in the electronic patient record.
Data collection will occur at 24, 48, 72, and 120 hours from the start of the first hemoadsorption procedure.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Aleksandr Burov, PHD
- Numero di telefono: +79854215478
- Email: Aleksander.bour@mail.ru
Luoghi di studio
-
-
-
Moscow, Russia
- Petrovsky National Research Centre of Surgery
-
Contatto:
- Maxim Babaev, MD, PHD
- Numero di telefono: +79160269066
- Email: maxbabaev@mail.ru
-
Moscow, Russia
- Bakulev Scientific Center of Cardiovascular Surgery
-
Contatto:
- Mikhail Yarustovskiy, MD, PHD
- Numero di telefono: +79104194682
- Email: mbyar@yandex.ru
-
Moscow, Russia
- City clinical hospital named after S. S. Yudin, Moscow City Health
-
Contatto:
- Nikolay Krotenko, PHD
- Numero di telefono: +79268664976
- Email: npkrotenko@gmail.com
-
Moscow, Russia
- City Clinical Hospital No 52, Moscow, Russia
-
Contatto:
- Rustam Iskhakov
- Numero di telefono: +79265317813
- Email: stamius@yandex.ru
-
Moscow, Russia
- Moscow Multi-disciplinary Clinical Center "Kommunarka"
-
Moscow, Russia
- Sklifosovsky Institute of Emergency Care
-
Contatto:
- Sergei Rei, PHD
- Numero di telefono: +79166001362
- Email: reysi@sklif.mos.ru
-
Rostov-on-Don, Russia
- National Medical Research Centre for Oncology Rostov-on-Don
-
Contatto:
- Natalia Ushakova, MD, PHD
- Numero di telefono: +79185533155
- Email: ndu2000@rambler.ru
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Septic shock according to SEPSIS-3 criteria
- Age: 18-80 years
- SOFA ≥9 points
- Diagnosis of septic shock established <12 hours ago
- Invasive hemodynamic monitoring
- Norepinephrine dose >0.2 mcg/kg/min
Exclusion Criteria:
- Absolute neutrophil count less than 500 cells/μL
- Pregnancy
- End-stage heart failure (NYHA stage IV)
- Pulmonary embolism with obstructive shock
- Ongoing bleeding
- Atonic coma
- More than 30 points on the MELD scale, class C on the Child-Pugh scale
- HIV infection
- Burns over 10% of the body surface area
- Patients with oncohematological diseases
- Patients with a recognized palliative status or the definition of "metastatic cancer"
- RRT using membranes with a high cutoff point and increased adsorption capacity within 72 hours from the initiation of the first hemoadsorption procedure
- Use of plasma exchange within 72 hours from the initiation of the first hemoadsorption procedure
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Inflammatory mediatiors adsorption with CytoSorb
Inflammatory mediatiors adsorption with EAA <0,6 with CytoSorb
|
Blood purification with Jafron HA 330
|
|
Comparatore attivo: Inflammatory mediatiors adsorption with Jafron HA 330
Inflammatory mediatiors adsorption with EAA <0,6 with Jafron HA 330
|
Blood purification with Jafron HA 330
|
|
Sperimentale: Endotoxin haemoadsorption with Toramyxin PMX 20R
Endotoxin haemoadsorption with EAA [0.6-0.9] with Toramyxin PMX 20R
|
Blood purification with Toramyxin PMX 20R
|
|
Comparatore attivo: Endotoxin haemoadsorption with Efferon LPS
Endotoxin haemoadsorption with EAA [0.6-0.9] with Efferon LPS
|
Blood purification with Efferon LPS
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
SOFA score
Lasso di tempo: Assessed at 72 hours after hemoadsorption initiation
|
MODS dynamics majored by SOFA (sequential organ failure assessment) score
|
Assessed at 72 hours after hemoadsorption initiation
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
VIS dynamics
Lasso di tempo: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
|
Vasoactive Inotropic Score (VIS) dynamics VIS = dopamine dose (mcg∕kg∕ min ) + dobutamine dose (mcg∕kg∕ min ) + 100 × epinephrine dose (mcg∕kg∕ min ) + 10 × milrinone dose (mcg∕kg∕ min ) + 10,000 × vasopressin dose (units∕kg∕ min ) + 100 × norepinephrine dose (mcg∕kg∕ min ) |
Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
|
|
NE dose dynamics
Lasso di tempo: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
|
Norepinephrine dose dynamics (mcg/kg/min)
|
Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
|
|
MAP/VIS dynamics
Lasso di tempo: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
|
Mean arterial pressure (MAP) to Vasoactive Inotropic Score (VIS) dynamics VIS = dopamine dose (mcg∕kg∕ min ) + dobutamine dose (mcg∕kg∕ min ) + 100 × epinephrine dose (mcg∕kg∕ min ) + 10 × milrinone dose (mcg∕kg∕ min ) + 10,000 × vasopressin dose (units∕kg∕ min ) + 100 × norepinephrine dose (mcg∕kg∕ min ) |
Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
|
|
P/f ratio dynamics
Lasso di tempo: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
|
Arterial oxygen partial pressure (PaO2)/fraction of inspired oxygen (FiO2) ratio (Horowitz index) dynamics
|
Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
|
|
Lactate level dynamics
Lasso di tempo: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
|
Lactate level dynamics (mmol/l)
|
Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
|
|
Total bilirubin level dynamics
Lasso di tempo: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
|
Total bilirubin level dynamics (mcmol/l)
|
Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
|
|
Indirect bilirubin level dynamics
Lasso di tempo: Time Frame: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
|
Indirect bilirubin level dynamics (mcmol/l)
|
Time Frame: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
|
|
Direct bilirubin level dynamics
Lasso di tempo: Time Frame: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
|
Direct bilirubin level dynamics (mcmol/l)
|
Time Frame: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
|
|
Ferritin level dynamics
Lasso di tempo: Time Frame: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
|
Ferritin level dynamics (mcg/l)
|
Time Frame: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
|
|
PCT level dynamics
Lasso di tempo: Time Frame: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
|
Procalcitonin (PCT) level dynamics (ng/ml)
|
Time Frame: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
|
|
CRP level dynamics
Lasso di tempo: Time Frame: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
|
C- reactive protein (CRP) level dynamics (mg/l)
|
Time Frame: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
|
|
NLR dynamics
Lasso di tempo: Time Frame: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
|
NLR (neutrophil-to-lymphocyte ratio) dynamics
|
Time Frame: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
|
|
PLR dynamics
Lasso di tempo: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
|
PLR (Platelet-to-lymphocyte ratio) dynamics
|
Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
|
|
TNF level dynamics
Lasso di tempo: Assessed at 3 time points: before hemoadsorption initiation (baseline); 48 hours and 72 hours after hemoadsorption initiation
|
TNF (Tumor necrosis factor-alpha) level dynamics (pg/ml)
|
Assessed at 3 time points: before hemoadsorption initiation (baseline); 48 hours and 72 hours after hemoadsorption initiation
|
|
IL 6 level dynamics
Lasso di tempo: Assessed at 3 time points: before hemoadsorption initiation (baseline); 48 hours and 72 hours after hemoadsorption initiation
|
IL 6 (Interleukin 6) level dynamics (pg/ml)
|
Assessed at 3 time points: before hemoadsorption initiation (baseline); 48 hours and 72 hours after hemoadsorption initiation
|
|
IL 10 level dynamics
Lasso di tempo: Time Frame: Assessed at 3 time points: before hemoadsorption initiation (baseline); 48 hours and 72 hours after hemoadsorption initiation
|
IL 10 (Interleukin 10) level dynamics (pg/ml)
|
Time Frame: Assessed at 3 time points: before hemoadsorption initiation (baseline); 48 hours and 72 hours after hemoadsorption initiation
|
|
28 - days mortality
Lasso di tempo: Will be calculated for 28 days after hemoadsorption initiation
|
28 - days mortality
|
Will be calculated for 28 days after hemoadsorption initiation
|
|
90 - days mortality
Lasso di tempo: Will be calculated for 90 days after hemoadsorption initiation
|
90 - days mortality
|
Will be calculated for 90 days after hemoadsorption initiation
|
|
SOFA dynamics
Lasso di tempo: Assessed at 4 time points: before hemoadsorption initiatioin (baseline); at 24, 48 and 120 hours after hemoadsorption initiation
|
MODS dynamics majored by SOFA (sequential organ failure assessment) score
|
Assessed at 4 time points: before hemoadsorption initiatioin (baseline); at 24, 48 and 120 hours after hemoadsorption initiation
|
|
SOFA 2 dynamics
Lasso di tempo: Assessed at 5 time points: before hemoadsorption initiatioin (baseline); at 24, 48, 72 and 120 hours after hemoadsorption initiation
|
MODS dynamics majored by SOFA 2 (sequential organ failure assessment) score
|
Assessed at 5 time points: before hemoadsorption initiatioin (baseline); at 24, 48, 72 and 120 hours after hemoadsorption initiation
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Ventilator-free days
Lasso di tempo: Will be calculated for 28 days after hemoadsorption initiation
|
Ventilator-free days
|
Will be calculated for 28 days after hemoadsorption initiation
|
|
Vasopressor-free days
Lasso di tempo: Will be calculated for 28 days after hemoadsorption initiation
|
Vasopressor-free days
|
Will be calculated for 28 days after hemoadsorption initiation
|
|
Dialysis-free days
Lasso di tempo: Will be calculated for 28 days after hemoadsorption initiation
|
Dialysis-free days
|
Will be calculated for 28 days after hemoadsorption initiation
|
|
Hospital length of stay
Lasso di tempo: Will be calculated for 28 days after hemoadsorption initiation
|
Hospital length of stay
|
Will be calculated for 28 days after hemoadsorption initiation
|
|
ICU length of stay
Lasso di tempo: Will be calculated for 28 days after hemoadsorption initiation
|
Intensive care unit (ICU) length of stay
|
Will be calculated for 28 days after hemoadsorption initiation
|
|
AEs
Lasso di tempo: Serious AEs will be reported up to Day 28
|
The safety will be assessed by analysing the number of adverse events (AEs) where causal relationship with the intervention cannot be excluded, up until Day 28.
|
Serious AEs will be reported up to Day 28
|
Collaboratori e investigatori
Collaboratori
Investigatori
- Direttore dello studio: Denis Protsenko, MD, PHD, Moscow Multi-disciplinary Clinical Center "Kommunarka"
Pubblicazioni e link utili
Pubblicazioni generali
- Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, Malcangi V, Petrini F, Volta G, Bobbio Pallavicini FM, Rottoli F, Giunta F, Ronco C. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009 Jun 17;301(23):2445-52. doi: 10.1001/jama.2009.856.
- Onuk S, Akin AK, Sari A, Gundogan K, Baskol G, Dogru K, Sungur M. The Clinical and Laboratory Efficacy of HA 330 Treatment Combined with Continuous Renal Replacement Therapy in Septic Shock Patients: A Case Series. Blood Purif. 2023;52(2):140-147. doi: 10.1159/000528150. Epub 2023 Jan 12.
- Mehta Y, Mehta C, Kumar A, George JV, Gupta A, Nanda S, Kochhar G, Raizada A. Experience with hemoadsorption (CytoSorb(R)) in the management of septic shock patients. World J Crit Care Med. 2020 Jan 31;9(1):1-12. doi: 10.5492/wjccm.v9.i1.1. eCollection 2020 Jan 31.
- Rey S, Kulabukhov VM, Popov A, Nikitina O, Berdnikov G, Magomedov M, Kim T, Masolitin S, Ignatenko O, Krotenko N, Marysheva A, Chaus N, Ohinko L, Mendibaev M, Chumachenko A, Pisarev V. HEMOPERFUSION USING THE LPS-SELECTIVE MESOPOROUS POLYMERIC ADSORBENT IN SEPTIC SHOCK: A MULTICENTER RANDOMIZED CLINICAL TRIAL. Shock. 2023 Jun 1;59(6):846-854. doi: 10.1097/SHK.0000000000002121. Epub 2023 Apr 6.
- Klein DJ, Foster D, Walker PM, Bagshaw SM, Mekonnen H, Antonelli M. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial. Intensive Care Med. 2018 Dec;44(12):2205-2212. doi: 10.1007/s00134-018-5463-7. Epub 2018 Nov 23.
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- HAdSS
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Periodo di condivisione IPD
Criteri di accesso alla condivisione IPD
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
- RSI
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Shock settico
-
Assistance Publique - Hôpitaux de ParisTraumabase Group; Capgemini Invent; Ecole polytechnique; EHESS (Ecole des hautes... e altri collaboratoriCompletatoFerite e lesioni | Shock emorragico | Shock traumaticoFrancia
-
King's College Hospital NHS TrustUniversity Hospital BirminghamCompletatoShock emorragico traumaticoRegno Unito
-
Haukeland University HospitalMinistry of Defence, NorwayCompletatoShock emorragico | Shock ipovolemicoNorvegia
-
Arsenal Medical, Inc.ReclutamentoTrauma | Shock emorragico | Emorragia dissanguante | Shock; TraumaticoStati Uniti
-
Massachusetts General HospitalBeth Israel Deaconess Medical Center; Boston Medical Center; Tufts Medical Center; Lahey Clinic e altri collaboratoriReclutamento
-
Jason SperryNational Heart, Lung, and Blood Institute (NHLBI)TerminatoShock emorragicoStati Uniti
-
University of Texas Southwestern Medical CenterUniversity of Washington; Resuscitation Outcomes ConsortiumCompletato
-
Artcline GmbHReclutamentoSepsi | Shock settico | Immunoparalisi nello Shock SetticoGermania
-
Ramathibodi HospitalSconosciutoShock settico | Shock refrattarioTailandia
-
German Center for Neurodegenerative Diseases (DZNE)University Hospital, BonnSconosciutoSepsi grave con shock settico | Sepsi grave senza shock setticoGermania
Prove cliniche su CytoSorb
-
Emanuela KellerCytoSorbents Europe GmbHTerminato
-
CytoSorbents, IncReclutamentoSepsi | Brucia | Shock settico | Trauma | Malattia infettiva | Pancreatite | Sindrome da distress respiratorio acuto | Trapianto di fegato; Complicazioni | Overdose di droga | Insufficienza epatica acuta | Shock cardiogenico | Rabdomiolisi | Acuta su insufficienza epatica cronica | Linfoistiocitosi emofagocitiche | Supporto... e altre condizioniAustria, Germania, Spagna, Italia, Polonia, Portogallo
-
Lund University HospitalCompletatoFallimento del trapianto di polmone | Trapianto di polmone; ComplicazioniSvezia
-
Emma HanssonCytoSorbents, IncCompletato
-
Institutul Clinic FundeniCompletato
-
Lund University HospitalReclutamentoFallimento del trapianto di polmone | Trapianto di polmone; ComplicazioniSvezia
-
Universitätsklinikum Hamburg-EppendorfCytoSorbents, IncReclutamento
-
Semmelweis UniversityCompletatoBypass cardiopolmonare | Trapianto cardiacoUngheria
-
University Magna GraeciaSconosciutoEmoassorbimento durante e dopo bypass cardiopolmonare per modulare la risposta infiammatoria (IMHeS)Risposta infiammatoria | Chirurgia cardiaca | Malattia renale cronicaItalia
-
Medical University of ViennaReclutamento